Breast Cancer Clinical Trials in San Antonio

Showing 201-220 of 412 trials

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

Active Not RecruitingPhase 3< 1 mile

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02488967

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Breast AdenocarcinomaEstrogen Receptor NegativeHER2/Neu Negative+7 more

NRG Oncology782 participantsStarted Jul 2015

Mobile, Alabama, United States • Mobile, Alabama, United States • Mobile, Alabama, United States +1293 more locations

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Breast Cancer Trials in Other Cities

Improving Adherence to EHT Among Breast Cancer Patients

PRS-343 in HER2-Positive Solid Tumors

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

LYT-100 in Patients With BCRL

Other Conditions in San Antonio